Parmax Pharma Limited (BSE: PARMAX.BO) Stock Competitors & Peer Comparison
See PARMAX.BO's competitors and their performance on the BSE and across the wider stock market.
Peer Comparison Table: Medical - Pharmaceuticals Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for PARMAX.BO and its BSE peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| PARMAX.BO | ₹129.90 | +1.96% | 486M | -11.68 | -₹11.12 | N/A |
| JBCHEPHARM.BO | ₹2,412.25 | -3.70% | 387.3B | 50.89 | ₹47.40 | +0.91% |
| WOCKPHARMA.NS | ₹1,886.30 | +3.04% | 306.5B | 143.88 | ₹13.11 | N/A |
| WOCKPHARMA.BO | ₹1,885.80 | +3.04% | 306.2B | 143.84 | ₹13.11 | N/A |
| MEDPLUS.NS | ₹689.55 | +5.07% | 82.8B | 37.31 | ₹18.48 | N/A |
| MEDPLUS.BO | ₹688.40 | +4.81% | 82.7B | 36.62 | ₹18.80 | N/A |
| SANOFI.NS | ₹3,352.80 | +0.96% | 77.2B | 22.09 | ₹151.80 | +3.67% |
| SANOFI.BO | ₹3,361.60 | +1.20% | 77.1B | 22.06 | ₹151.80 | +3.67% |
| SUPRIYA.NS | ₹805.45 | -0.77% | 64.8B | 30.98 | ₹26.00 | +0.12% |
| SUPRIYA.BO | ₹805.00 | -0.94% | 64.8B | 32.63 | ₹24.67 | +0.12% |
Stock Comparison
J. B. Chemicals & Pharmaceuticals Limited (BSE: JBCHEPHARM.BO)
PARMAX.BO vs JBCHEPHARM.BO Comparison August 2026
Parmax Pharma Limited (BSE: PARMAX.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PARMAX.BO stands at 486M. In comparison, JBCHEPHARM.BO has a market cap of 387.3B. Regarding current trading prices, PARMAX.BO is priced at ₹129.90 on the BSE, while JBCHEPHARM.BO trades at ₹2,412.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PARMAX.BO currently has a P/E ratio of -11.68, whereas JBCHEPHARM.BO's P/E ratio is 50.89. In terms of profitability, PARMAX.BO's ROE is +0.96%, compared to JBCHEPHARM.BO's ROE of +0.19%. Regarding short-term risk, PARMAX.BO is less volatile compared to JBCHEPHARM.BO. This indicates lower risk in terms of short-term price fluctuations for PARMAX.BO.Check JBCHEPHARM.BO's competition here
Wockhardt Limited (NSE: WOCKPHARMA.NS)
PARMAX.BO vs WOCKPHARMA.NS Comparison August 2026
Parmax Pharma Limited (BSE: PARMAX.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PARMAX.BO stands at 486M. In comparison, WOCKPHARMA.NS has a market cap of 306.5B. Regarding current trading prices, PARMAX.BO is priced at ₹129.90 on the BSE, while WOCKPHARMA.NS trades at ₹1,886.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PARMAX.BO currently has a P/E ratio of -11.68, whereas WOCKPHARMA.NS's P/E ratio is 143.88. In terms of profitability, PARMAX.BO's ROE is +0.96%, compared to WOCKPHARMA.NS's ROE of +0.09%. Regarding short-term risk, PARMAX.BO is less volatile compared to WOCKPHARMA.NS. This indicates lower risk in terms of short-term price fluctuations for PARMAX.BO.Check WOCKPHARMA.NS's competition here
Wockhardt Limited (BSE: WOCKPHARMA.BO)
PARMAX.BO vs WOCKPHARMA.BO Comparison August 2026
Parmax Pharma Limited (BSE: PARMAX.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PARMAX.BO stands at 486M. In comparison, WOCKPHARMA.BO has a market cap of 306.2B. Regarding current trading prices, PARMAX.BO is priced at ₹129.90 on the BSE, while WOCKPHARMA.BO trades at ₹1,885.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PARMAX.BO currently has a P/E ratio of -11.68, whereas WOCKPHARMA.BO's P/E ratio is 143.84. In terms of profitability, PARMAX.BO's ROE is +0.96%, compared to WOCKPHARMA.BO's ROE of +0.09%. Regarding short-term risk, PARMAX.BO is less volatile compared to WOCKPHARMA.BO. This indicates lower risk in terms of short-term price fluctuations for PARMAX.BO.Check WOCKPHARMA.BO's competition here
MedPlus Health Services Limited (NSE: MEDPLUS.NS)
PARMAX.BO vs MEDPLUS.NS Comparison August 2026
Parmax Pharma Limited (BSE: PARMAX.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PARMAX.BO stands at 486M. In comparison, MEDPLUS.NS has a market cap of 82.8B. Regarding current trading prices, PARMAX.BO is priced at ₹129.90 on the BSE, while MEDPLUS.NS trades at ₹689.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PARMAX.BO currently has a P/E ratio of -11.68, whereas MEDPLUS.NS's P/E ratio is 37.31. In terms of profitability, PARMAX.BO's ROE is +0.96%, compared to MEDPLUS.NS's ROE of +0.11%. Regarding short-term risk, PARMAX.BO is less volatile compared to MEDPLUS.NS. This indicates lower risk in terms of short-term price fluctuations for PARMAX.BO.Check MEDPLUS.NS's competition here
MedPlus Health Services Limited (BSE: MEDPLUS.BO)
PARMAX.BO vs MEDPLUS.BO Comparison August 2026
Parmax Pharma Limited (BSE: PARMAX.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PARMAX.BO stands at 486M. In comparison, MEDPLUS.BO has a market cap of 82.7B. Regarding current trading prices, PARMAX.BO is priced at ₹129.90 on the BSE, while MEDPLUS.BO trades at ₹688.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PARMAX.BO currently has a P/E ratio of -11.68, whereas MEDPLUS.BO's P/E ratio is 36.62. In terms of profitability, PARMAX.BO's ROE is +0.96%, compared to MEDPLUS.BO's ROE of +0.11%. Regarding short-term risk, PARMAX.BO is less volatile compared to MEDPLUS.BO. This indicates lower risk in terms of short-term price fluctuations for PARMAX.BO.Check MEDPLUS.BO's competition here
Sanofi India Limited (NSE: SANOFI.NS)
PARMAX.BO vs SANOFI.NS Comparison August 2026
Parmax Pharma Limited (BSE: PARMAX.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PARMAX.BO stands at 486M. In comparison, SANOFI.NS has a market cap of 77.2B. Regarding current trading prices, PARMAX.BO is priced at ₹129.90 on the BSE, while SANOFI.NS trades at ₹3,352.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PARMAX.BO currently has a P/E ratio of -11.68, whereas SANOFI.NS's P/E ratio is 22.09. In terms of profitability, PARMAX.BO's ROE is +0.96%, compared to SANOFI.NS's ROE of +0.40%. Regarding short-term risk, PARMAX.BO is less volatile compared to SANOFI.NS. This indicates lower risk in terms of short-term price fluctuations for PARMAX.BO.Check SANOFI.NS's competition here
Sanofi India Limited (BSE: SANOFI.BO)
PARMAX.BO vs SANOFI.BO Comparison August 2026
Parmax Pharma Limited (BSE: PARMAX.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PARMAX.BO stands at 486M. In comparison, SANOFI.BO has a market cap of 77.1B. Regarding current trading prices, PARMAX.BO is priced at ₹129.90 on the BSE, while SANOFI.BO trades at ₹3,361.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PARMAX.BO currently has a P/E ratio of -11.68, whereas SANOFI.BO's P/E ratio is 22.06. In terms of profitability, PARMAX.BO's ROE is +0.96%, compared to SANOFI.BO's ROE of +0.40%. Regarding short-term risk, PARMAX.BO is less volatile compared to SANOFI.BO. This indicates lower risk in terms of short-term price fluctuations for PARMAX.BO.Check SANOFI.BO's competition here
Supriya Lifescience Limited (NSE: SUPRIYA.NS)
PARMAX.BO vs SUPRIYA.NS Comparison August 2026
Parmax Pharma Limited (BSE: PARMAX.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PARMAX.BO stands at 486M. In comparison, SUPRIYA.NS has a market cap of 64.8B. Regarding current trading prices, PARMAX.BO is priced at ₹129.90 on the BSE, while SUPRIYA.NS trades at ₹805.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PARMAX.BO currently has a P/E ratio of -11.68, whereas SUPRIYA.NS's P/E ratio is 30.98. In terms of profitability, PARMAX.BO's ROE is +0.96%, compared to SUPRIYA.NS's ROE of +0.18%. Regarding short-term risk, PARMAX.BO is less volatile compared to SUPRIYA.NS. This indicates lower risk in terms of short-term price fluctuations for PARMAX.BO.Check SUPRIYA.NS's competition here
Supriya Lifescience Ltd (BSE: SUPRIYA.BO)
PARMAX.BO vs SUPRIYA.BO Comparison August 2026
Parmax Pharma Limited (BSE: PARMAX.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PARMAX.BO stands at 486M. In comparison, SUPRIYA.BO has a market cap of 64.8B. Regarding current trading prices, PARMAX.BO is priced at ₹129.90 on the BSE, while SUPRIYA.BO trades at ₹805.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PARMAX.BO currently has a P/E ratio of -11.68, whereas SUPRIYA.BO's P/E ratio is 32.63. In terms of profitability, PARMAX.BO's ROE is +0.96%, compared to SUPRIYA.BO's ROE of +0.18%. Regarding short-term risk, PARMAX.BO is less volatile compared to SUPRIYA.BO. This indicates lower risk in terms of short-term price fluctuations for PARMAX.BO.Check SUPRIYA.BO's competition here
Kwality Pharmaceuticals Limited (BSE: KPL.BO)
PARMAX.BO vs KPL.BO Comparison August 2026
Parmax Pharma Limited (BSE: PARMAX.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PARMAX.BO stands at 486M. In comparison, KPL.BO has a market cap of 34.8B. Regarding current trading prices, PARMAX.BO is priced at ₹129.90 on the BSE, while KPL.BO trades at ₹3,357.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PARMAX.BO currently has a P/E ratio of -11.68, whereas KPL.BO's P/E ratio is 83.89. In terms of profitability, PARMAX.BO's ROE is +0.96%, compared to KPL.BO's ROE of +0.28%. Regarding short-term risk, PARMAX.BO is less volatile compared to KPL.BO. This indicates lower risk in terms of short-term price fluctuations for PARMAX.BO.Check KPL.BO's competition here
Hikal Limited (NSE: HIKAL.NS)
PARMAX.BO vs HIKAL.NS Comparison August 2026
Parmax Pharma Limited (BSE: PARMAX.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PARMAX.BO stands at 486M. In comparison, HIKAL.NS has a market cap of 26.6B. Regarding current trading prices, PARMAX.BO is priced at ₹129.90 on the BSE, while HIKAL.NS trades at ₹215.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PARMAX.BO currently has a P/E ratio of -11.68, whereas HIKAL.NS's P/E ratio is 15.43. In terms of profitability, PARMAX.BO's ROE is +0.96%, compared to HIKAL.NS's ROE of -0.03%. Regarding short-term risk, PARMAX.BO is less volatile compared to HIKAL.NS. This indicates lower risk in terms of short-term price fluctuations for PARMAX.BO.Check HIKAL.NS's competition here
Hikal Limited (BSE: HIKAL.BO)
PARMAX.BO vs HIKAL.BO Comparison August 2026
Parmax Pharma Limited (BSE: PARMAX.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PARMAX.BO stands at 486M. In comparison, HIKAL.BO has a market cap of 26.6B. Regarding current trading prices, PARMAX.BO is priced at ₹129.90 on the BSE, while HIKAL.BO trades at ₹216.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PARMAX.BO currently has a P/E ratio of -11.68, whereas HIKAL.BO's P/E ratio is 188.09. In terms of profitability, PARMAX.BO's ROE is +0.96%, compared to HIKAL.BO's ROE of -0.03%. Regarding short-term risk, PARMAX.BO is less volatile compared to HIKAL.BO. This indicates lower risk in terms of short-term price fluctuations for PARMAX.BO.Check HIKAL.BO's competition here
Fredun Pharmaceuticals Limited (BSE: FREDUN.BO)
PARMAX.BO vs FREDUN.BO Comparison August 2026
Parmax Pharma Limited (BSE: PARMAX.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PARMAX.BO stands at 486M. In comparison, FREDUN.BO has a market cap of 23.7B. Regarding current trading prices, PARMAX.BO is priced at ₹129.90 on the BSE, while FREDUN.BO trades at ₹1,435.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PARMAX.BO currently has a P/E ratio of -11.68, whereas FREDUN.BO's P/E ratio is 56.48. In terms of profitability, PARMAX.BO's ROE is +0.96%, compared to FREDUN.BO's ROE of +0.20%. Regarding short-term risk, PARMAX.BO is less volatile compared to FREDUN.BO. This indicates lower risk in terms of short-term price fluctuations for PARMAX.BO.Check FREDUN.BO's competition here
Shukra Pharmaceuticals Limited (BSE: SHUKRAPHAR.BO)
PARMAX.BO vs SHUKRAPHAR.BO Comparison August 2026
Parmax Pharma Limited (BSE: PARMAX.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PARMAX.BO stands at 486M. In comparison, SHUKRAPHAR.BO has a market cap of 19.3B. Regarding current trading prices, PARMAX.BO is priced at ₹129.90 on the BSE, while SHUKRAPHAR.BO trades at ₹44.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PARMAX.BO currently has a P/E ratio of -11.68, whereas SHUKRAPHAR.BO's P/E ratio is 88.22. In terms of profitability, PARMAX.BO's ROE is +0.96%, compared to SHUKRAPHAR.BO's ROE of +0.48%. Regarding short-term risk, PARMAX.BO is less volatile compared to SHUKRAPHAR.BO. This indicates lower risk in terms of short-term price fluctuations for PARMAX.BO.Check SHUKRAPHAR.BO's competition here
Accent Microcell Limited (NSE: ACCENTMIC.NS)
PARMAX.BO vs ACCENTMIC.NS Comparison August 2026
Parmax Pharma Limited (BSE: PARMAX.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PARMAX.BO stands at 486M. In comparison, ACCENTMIC.NS has a market cap of 14.5B. Regarding current trading prices, PARMAX.BO is priced at ₹129.90 on the BSE, while ACCENTMIC.NS trades at ₹605.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PARMAX.BO currently has a P/E ratio of -11.68, whereas ACCENTMIC.NS's P/E ratio is 32.44. In terms of profitability, PARMAX.BO's ROE is +0.96%, compared to ACCENTMIC.NS's ROE of N/A. Regarding short-term risk, PARMAX.BO is less volatile compared to ACCENTMIC.NS. This indicates lower risk in terms of short-term price fluctuations for PARMAX.BO.Check ACCENTMIC.NS's competition here
Remus Pharmaceuticals Ltd. (NSE: REMUS.NS)
PARMAX.BO vs REMUS.NS Comparison August 2026
Parmax Pharma Limited (BSE: PARMAX.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PARMAX.BO stands at 486M. In comparison, REMUS.NS has a market cap of 11.3B. Regarding current trading prices, PARMAX.BO is priced at ₹129.90 on the BSE, while REMUS.NS trades at ₹961.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PARMAX.BO currently has a P/E ratio of -11.68, whereas REMUS.NS's P/E ratio is 26.87. In terms of profitability, PARMAX.BO's ROE is +0.96%, compared to REMUS.NS's ROE of N/A. Regarding short-term risk, PARMAX.BO is less volatile compared to REMUS.NS. This indicates lower risk in terms of short-term price fluctuations for PARMAX.BO.Check REMUS.NS's competition here
One Global Service Provider Ltd. (BSE: ONEGLOBAL.BO)
PARMAX.BO vs ONEGLOBAL.BO Comparison August 2026
Parmax Pharma Limited (BSE: PARMAX.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PARMAX.BO stands at 486M. In comparison, ONEGLOBAL.BO has a market cap of 10.8B. Regarding current trading prices, PARMAX.BO is priced at ₹129.90 on the BSE, while ONEGLOBAL.BO trades at ₹552.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PARMAX.BO currently has a P/E ratio of -11.68, whereas ONEGLOBAL.BO's P/E ratio is 15.54. In terms of profitability, PARMAX.BO's ROE is +0.96%, compared to ONEGLOBAL.BO's ROE of +0.71%. Regarding short-term risk, PARMAX.BO is less volatile compared to ONEGLOBAL.BO. This indicates lower risk in terms of short-term price fluctuations for PARMAX.BO.Check ONEGLOBAL.BO's competition here
Bharat Parenterals Limited (BSE: BPLPHARMA.BO)
PARMAX.BO vs BPLPHARMA.BO Comparison August 2026
Parmax Pharma Limited (BSE: PARMAX.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PARMAX.BO stands at 486M. In comparison, BPLPHARMA.BO has a market cap of 9.5B. Regarding current trading prices, PARMAX.BO is priced at ₹129.90 on the BSE, while BPLPHARMA.BO trades at ₹1,382.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PARMAX.BO currently has a P/E ratio of -11.68, whereas BPLPHARMA.BO's P/E ratio is -118.70. In terms of profitability, PARMAX.BO's ROE is +0.96%, compared to BPLPHARMA.BO's ROE of -0.05%. Regarding short-term risk, PARMAX.BO is less volatile compared to BPLPHARMA.BO. This indicates lower risk in terms of short-term price fluctuations for PARMAX.BO.Check BPLPHARMA.BO's competition here
Sudarshan Pharma Industries Ltd. (BSE: SUDARSHAN.BO)
PARMAX.BO vs SUDARSHAN.BO Comparison August 2026
Parmax Pharma Limited (BSE: PARMAX.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PARMAX.BO stands at 486M. In comparison, SUDARSHAN.BO has a market cap of 9.5B. Regarding current trading prices, PARMAX.BO is priced at ₹129.90 on the BSE, while SUDARSHAN.BO trades at ₹38.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PARMAX.BO currently has a P/E ratio of -11.68, whereas SUDARSHAN.BO's P/E ratio is 39.35. In terms of profitability, PARMAX.BO's ROE is +0.96%, compared to SUDARSHAN.BO's ROE of +0.18%. Regarding short-term risk, PARMAX.BO is less volatile compared to SUDARSHAN.BO. This indicates lower risk in terms of short-term price fluctuations for PARMAX.BO.Check SUDARSHAN.BO's competition here
Sastasundar Ventures Limited (NSE: SASTASUNDR.NS)
PARMAX.BO vs SASTASUNDR.NS Comparison August 2026
Parmax Pharma Limited (BSE: PARMAX.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PARMAX.BO stands at 486M. In comparison, SASTASUNDR.NS has a market cap of 9B. Regarding current trading prices, PARMAX.BO is priced at ₹129.90 on the BSE, while SASTASUNDR.NS trades at ₹282.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PARMAX.BO currently has a P/E ratio of -11.68, whereas SASTASUNDR.NS's P/E ratio is 34.59. In terms of profitability, PARMAX.BO's ROE is +0.96%, compared to SASTASUNDR.NS's ROE of +0.00%. Regarding short-term risk, PARMAX.BO is less volatile compared to SASTASUNDR.NS. This indicates lower risk in terms of short-term price fluctuations for PARMAX.BO.Check SASTASUNDR.NS's competition here
Vikram Thermo (India) Limited (BSE: VIKRAMTH.BO)
PARMAX.BO vs VIKRAMTH.BO Comparison August 2026
Parmax Pharma Limited (BSE: PARMAX.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PARMAX.BO stands at 486M. In comparison, VIKRAMTH.BO has a market cap of 9B. Regarding current trading prices, PARMAX.BO is priced at ₹129.90 on the BSE, while VIKRAMTH.BO trades at ₹285.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PARMAX.BO currently has a P/E ratio of -11.68, whereas VIKRAMTH.BO's P/E ratio is 35.78. In terms of profitability, PARMAX.BO's ROE is +0.96%, compared to VIKRAMTH.BO's ROE of +0.32%. Regarding short-term risk, PARMAX.BO is less volatile compared to VIKRAMTH.BO. This indicates lower risk in terms of short-term price fluctuations for PARMAX.BO.Check VIKRAMTH.BO's competition here
Praveg Ltd. (BSE: PRAVEG.BO)
PARMAX.BO vs PRAVEG.BO Comparison August 2026
Parmax Pharma Limited (BSE: PARMAX.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PARMAX.BO stands at 486M. In comparison, PRAVEG.BO has a market cap of 7B. Regarding current trading prices, PARMAX.BO is priced at ₹129.90 on the BSE, while PRAVEG.BO trades at ₹268.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PARMAX.BO currently has a P/E ratio of -11.68, whereas PRAVEG.BO's P/E ratio is 37.84. In terms of profitability, PARMAX.BO's ROE is +0.96%, compared to PRAVEG.BO's ROE of -0.04%. Regarding short-term risk, PARMAX.BO is less volatile compared to PRAVEG.BO. This indicates lower risk in terms of short-term price fluctuations for PARMAX.BO.Check PRAVEG.BO's competition here
Shree Ganesh Remedies Limited (BSE: SGRL.BO)
PARMAX.BO vs SGRL.BO Comparison August 2026
Parmax Pharma Limited (BSE: PARMAX.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PARMAX.BO stands at 486M. In comparison, SGRL.BO has a market cap of 6.5B. Regarding current trading prices, PARMAX.BO is priced at ₹129.90 on the BSE, while SGRL.BO trades at ₹506.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PARMAX.BO currently has a P/E ratio of -11.68, whereas SGRL.BO's P/E ratio is 39.13. In terms of profitability, PARMAX.BO's ROE is +0.96%, compared to SGRL.BO's ROE of +0.10%. Regarding short-term risk, PARMAX.BO is less volatile compared to SGRL.BO. This indicates lower risk in terms of short-term price fluctuations for PARMAX.BO.Check SGRL.BO's competition here
Albert David Limited (BSE: ALBERTDA.BO)
PARMAX.BO vs ALBERTDA.BO Comparison August 2026
Parmax Pharma Limited (BSE: PARMAX.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PARMAX.BO stands at 486M. In comparison, ALBERTDA.BO has a market cap of 6.2B. Regarding current trading prices, PARMAX.BO is priced at ₹129.90 on the BSE, while ALBERTDA.BO trades at ₹1,084.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PARMAX.BO currently has a P/E ratio of -11.68, whereas ALBERTDA.BO's P/E ratio is 32.30. In terms of profitability, PARMAX.BO's ROE is +0.96%, compared to ALBERTDA.BO's ROE of -0.01%. Regarding short-term risk, PARMAX.BO is less volatile compared to ALBERTDA.BO. This indicates lower risk in terms of short-term price fluctuations for PARMAX.BO.Check ALBERTDA.BO's competition here
Bafna Pharmaceuticals Ltd. (BSE: BAFNAPH.BO)
PARMAX.BO vs BAFNAPH.BO Comparison August 2026
Parmax Pharma Limited (BSE: PARMAX.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PARMAX.BO stands at 486M. In comparison, BAFNAPH.BO has a market cap of 5.7B. Regarding current trading prices, PARMAX.BO is priced at ₹129.90 on the BSE, while BAFNAPH.BO trades at ₹247.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PARMAX.BO currently has a P/E ratio of -11.68, whereas BAFNAPH.BO's P/E ratio is 52.67. In terms of profitability, PARMAX.BO's ROE is +0.96%, compared to BAFNAPH.BO's ROE of +0.09%. Regarding short-term risk, PARMAX.BO is less volatile compared to BAFNAPH.BO. This indicates lower risk in terms of short-term price fluctuations for PARMAX.BO.Check BAFNAPH.BO's competition here
Bafna Pharmaceuticals Limited (NSE: BAFNAPH.NS)
PARMAX.BO vs BAFNAPH.NS Comparison August 2026
Parmax Pharma Limited (BSE: PARMAX.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PARMAX.BO stands at 486M. In comparison, BAFNAPH.NS has a market cap of 5.7B. Regarding current trading prices, PARMAX.BO is priced at ₹129.90 on the BSE, while BAFNAPH.NS trades at ₹242.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PARMAX.BO currently has a P/E ratio of -11.68, whereas BAFNAPH.NS's P/E ratio is 51.70. In terms of profitability, PARMAX.BO's ROE is +0.96%, compared to BAFNAPH.NS's ROE of +0.09%. Regarding short-term risk, PARMAX.BO is less volatile compared to BAFNAPH.NS. This indicates lower risk in terms of short-term price fluctuations for PARMAX.BO.Check BAFNAPH.NS's competition here
Jenburkt Pharmaceuticals Limited (BSE: JENBURPH.BO)
PARMAX.BO vs JENBURPH.BO Comparison August 2026
Parmax Pharma Limited (BSE: PARMAX.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PARMAX.BO stands at 486M. In comparison, JENBURPH.BO has a market cap of 4.6B. Regarding current trading prices, PARMAX.BO is priced at ₹129.90 on the BSE, while JENBURPH.BO trades at ₹1,034.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PARMAX.BO currently has a P/E ratio of -11.68, whereas JENBURPH.BO's P/E ratio is 20.05. In terms of profitability, PARMAX.BO's ROE is +0.96%, compared to JENBURPH.BO's ROE of +0.18%. Regarding short-term risk, PARMAX.BO is less volatile compared to JENBURPH.BO. This indicates lower risk in terms of short-term price fluctuations for PARMAX.BO.Check JENBURPH.BO's competition here
Transchem Limited (BSE: TRANSCHEM.BO)
PARMAX.BO vs TRANSCHEM.BO Comparison August 2026
Parmax Pharma Limited (BSE: PARMAX.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PARMAX.BO stands at 486M. In comparison, TRANSCHEM.BO has a market cap of 4B. Regarding current trading prices, PARMAX.BO is priced at ₹129.90 on the BSE, while TRANSCHEM.BO trades at ₹326.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PARMAX.BO currently has a P/E ratio of -11.68, whereas TRANSCHEM.BO's P/E ratio is 86.53. In terms of profitability, PARMAX.BO's ROE is +0.96%, compared to TRANSCHEM.BO's ROE of +0.08%. Regarding short-term risk, PARMAX.BO is less volatile compared to TRANSCHEM.BO. This indicates lower risk in terms of short-term price fluctuations for PARMAX.BO.Check TRANSCHEM.BO's competition here
Infinium Pharmachem Ltd. (NSE: INFINIUM.NS)
PARMAX.BO vs INFINIUM.NS Comparison August 2026
Parmax Pharma Limited (BSE: PARMAX.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PARMAX.BO stands at 486M. In comparison, INFINIUM.NS has a market cap of 3.5B. Regarding current trading prices, PARMAX.BO is priced at ₹129.90 on the BSE, while INFINIUM.NS trades at ₹227.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PARMAX.BO currently has a P/E ratio of -11.68, whereas INFINIUM.NS's P/E ratio is 37.77. In terms of profitability, PARMAX.BO's ROE is +0.96%, compared to INFINIUM.NS's ROE of N/A. Regarding short-term risk, PARMAX.BO is less volatile compared to INFINIUM.NS. This indicates lower risk in terms of short-term price fluctuations for PARMAX.BO.Check INFINIUM.NS's competition here
Ambalal Sarabhai Enterprises Limited (BSE: AMBALALSA.BO)
PARMAX.BO vs AMBALALSA.BO Comparison August 2026
Parmax Pharma Limited (BSE: PARMAX.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PARMAX.BO stands at 486M. In comparison, AMBALALSA.BO has a market cap of 3.5B. Regarding current trading prices, PARMAX.BO is priced at ₹129.90 on the BSE, while AMBALALSA.BO trades at ₹45.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PARMAX.BO currently has a P/E ratio of -11.68, whereas AMBALALSA.BO's P/E ratio is 19.52. In terms of profitability, PARMAX.BO's ROE is +0.96%, compared to AMBALALSA.BO's ROE of +0.09%. Regarding short-term risk, PARMAX.BO is less volatile compared to AMBALALSA.BO. This indicates lower risk in terms of short-term price fluctuations for PARMAX.BO.Check AMBALALSA.BO's competition here
Trident Lifeline Limited (BSE: TLL.BO)
PARMAX.BO vs TLL.BO Comparison August 2026
Parmax Pharma Limited (BSE: PARMAX.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PARMAX.BO stands at 486M. In comparison, TLL.BO has a market cap of 3.4B. Regarding current trading prices, PARMAX.BO is priced at ₹129.90 on the BSE, while TLL.BO trades at ₹282.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PARMAX.BO currently has a P/E ratio of -11.68, whereas TLL.BO's P/E ratio is 17.30. In terms of profitability, PARMAX.BO's ROE is +0.96%, compared to TLL.BO's ROE of +0.23%. Regarding short-term risk, PARMAX.BO is less volatile compared to TLL.BO. This indicates lower risk in terms of short-term price fluctuations for PARMAX.BO.Check TLL.BO's competition here
BDH Industries Limited (BSE: BDH.BO)
PARMAX.BO vs BDH.BO Comparison August 2026
Parmax Pharma Limited (BSE: PARMAX.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PARMAX.BO stands at 486M. In comparison, BDH.BO has a market cap of 3.1B. Regarding current trading prices, PARMAX.BO is priced at ₹129.90 on the BSE, while BDH.BO trades at ₹540.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PARMAX.BO currently has a P/E ratio of -11.68, whereas BDH.BO's P/E ratio is 36.73. In terms of profitability, PARMAX.BO's ROE is +0.96%, compared to BDH.BO's ROE of +0.16%. Regarding short-term risk, PARMAX.BO is less volatile compared to BDH.BO. This indicates lower risk in terms of short-term price fluctuations for PARMAX.BO.Check BDH.BO's competition here
Gennex Laboratories Limited (BSE: GENNEX.BO)
PARMAX.BO vs GENNEX.BO Comparison August 2026
Parmax Pharma Limited (BSE: PARMAX.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PARMAX.BO stands at 486M. In comparison, GENNEX.BO has a market cap of 3.1B. Regarding current trading prices, PARMAX.BO is priced at ₹129.90 on the BSE, while GENNEX.BO trades at ₹12.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PARMAX.BO currently has a P/E ratio of -11.68, whereas GENNEX.BO's P/E ratio is 15.63. In terms of profitability, PARMAX.BO's ROE is +0.96%, compared to GENNEX.BO's ROE of +0.09%. Regarding short-term risk, PARMAX.BO is less volatile compared to GENNEX.BO. This indicates lower risk in terms of short-term price fluctuations for PARMAX.BO.Check GENNEX.BO's competition here
Zenotech Laboratories Limited (BSE: ZENOTECH.BO)
PARMAX.BO vs ZENOTECH.BO Comparison August 2026
Parmax Pharma Limited (BSE: PARMAX.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PARMAX.BO stands at 486M. In comparison, ZENOTECH.BO has a market cap of 2.8B. Regarding current trading prices, PARMAX.BO is priced at ₹129.90 on the BSE, while ZENOTECH.BO trades at ₹46.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PARMAX.BO currently has a P/E ratio of -11.68, whereas ZENOTECH.BO's P/E ratio is 149.19. In terms of profitability, PARMAX.BO's ROE is +0.96%, compared to ZENOTECH.BO's ROE of -0.03%. Regarding short-term risk, PARMAX.BO is less volatile compared to ZENOTECH.BO. This indicates lower risk in terms of short-term price fluctuations for PARMAX.BO.Check ZENOTECH.BO's competition here
Kerala Ayurveda Limited (BSE: KERALAYUR.BO)
PARMAX.BO vs KERALAYUR.BO Comparison August 2026
Parmax Pharma Limited (BSE: PARMAX.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PARMAX.BO stands at 486M. In comparison, KERALAYUR.BO has a market cap of 2.5B. Regarding current trading prices, PARMAX.BO is priced at ₹129.90 on the BSE, while KERALAYUR.BO trades at ₹189.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PARMAX.BO currently has a P/E ratio of -11.68, whereas KERALAYUR.BO's P/E ratio is -20.70. In terms of profitability, PARMAX.BO's ROE is +0.96%, compared to KERALAYUR.BO's ROE of -2.76%. Regarding short-term risk, PARMAX.BO is less volatile compared to KERALAYUR.BO. This indicates lower risk in terms of short-term price fluctuations for PARMAX.BO.Check KERALAYUR.BO's competition here
Sanjivani Paranteral Limited. (BSE: SANJIVIN.BO)
PARMAX.BO vs SANJIVIN.BO Comparison August 2026
Parmax Pharma Limited (BSE: PARMAX.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PARMAX.BO stands at 486M. In comparison, SANJIVIN.BO has a market cap of 2.4B. Regarding current trading prices, PARMAX.BO is priced at ₹129.90 on the BSE, while SANJIVIN.BO trades at ₹193.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PARMAX.BO currently has a P/E ratio of -11.68, whereas SANJIVIN.BO's P/E ratio is 51.44. In terms of profitability, PARMAX.BO's ROE is +0.96%, compared to SANJIVIN.BO's ROE of +0.17%. Regarding short-term risk, PARMAX.BO is less volatile compared to SANJIVIN.BO. This indicates lower risk in terms of short-term price fluctuations for PARMAX.BO.Check SANJIVIN.BO's competition here
Oxygenta Pharmaceutical Ltd. (BSE: OXYGENTAPH.BO)
PARMAX.BO vs OXYGENTAPH.BO Comparison August 2026
Parmax Pharma Limited (BSE: PARMAX.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PARMAX.BO stands at 486M. In comparison, OXYGENTAPH.BO has a market cap of 2.4B. Regarding current trading prices, PARMAX.BO is priced at ₹129.90 on the BSE, while OXYGENTAPH.BO trades at ₹63.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PARMAX.BO currently has a P/E ratio of -11.68, whereas OXYGENTAPH.BO's P/E ratio is -63.71. In terms of profitability, PARMAX.BO's ROE is +0.96%, compared to OXYGENTAPH.BO's ROE of +0.39%. Regarding short-term risk, PARMAX.BO is less volatile compared to OXYGENTAPH.BO. This indicates lower risk in terms of short-term price fluctuations for PARMAX.BO.Check OXYGENTAPH.BO's competition here
Coral Laboratories Limited (BSE: CORALAB.BO)
PARMAX.BO vs CORALAB.BO Comparison August 2026
Parmax Pharma Limited (BSE: PARMAX.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PARMAX.BO stands at 486M. In comparison, CORALAB.BO has a market cap of 2.3B. Regarding current trading prices, PARMAX.BO is priced at ₹129.90 on the BSE, while CORALAB.BO trades at ₹650.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PARMAX.BO currently has a P/E ratio of -11.68, whereas CORALAB.BO's P/E ratio is 17.14. In terms of profitability, PARMAX.BO's ROE is +0.96%, compared to CORALAB.BO's ROE of +0.09%. Regarding short-term risk, PARMAX.BO is less volatile compared to CORALAB.BO. This indicates lower risk in terms of short-term price fluctuations for PARMAX.BO.Check CORALAB.BO's competition here
Panchsheel Organics Limited (BSE: PANCHSHEEL.BO)
PARMAX.BO vs PANCHSHEEL.BO Comparison August 2026
Parmax Pharma Limited (BSE: PARMAX.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PARMAX.BO stands at 486M. In comparison, PANCHSHEEL.BO has a market cap of 1.6B. Regarding current trading prices, PARMAX.BO is priced at ₹129.90 on the BSE, while PANCHSHEEL.BO trades at ₹118.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PARMAX.BO currently has a P/E ratio of -11.68, whereas PANCHSHEEL.BO's P/E ratio is 14.44. In terms of profitability, PARMAX.BO's ROE is +0.96%, compared to PANCHSHEEL.BO's ROE of +0.07%. Regarding short-term risk, PARMAX.BO is less volatile compared to PANCHSHEEL.BO. This indicates lower risk in terms of short-term price fluctuations for PARMAX.BO.Check PANCHSHEEL.BO's competition here
Syschem (India) Limited (BSE: SYSCHEM.BO)
PARMAX.BO vs SYSCHEM.BO Comparison August 2026
Parmax Pharma Limited (BSE: PARMAX.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PARMAX.BO stands at 486M. In comparison, SYSCHEM.BO has a market cap of 1.5B. Regarding current trading prices, PARMAX.BO is priced at ₹129.90 on the BSE, while SYSCHEM.BO trades at ₹30.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PARMAX.BO currently has a P/E ratio of -11.68, whereas SYSCHEM.BO's P/E ratio is 510.83. In terms of profitability, PARMAX.BO's ROE is +0.96%, compared to SYSCHEM.BO's ROE of +0.06%. Regarding short-term risk, PARMAX.BO is less volatile compared to SYSCHEM.BO. This indicates lower risk in terms of short-term price fluctuations for PARMAX.BO.Check SYSCHEM.BO's competition here
Auro Laboratories Limited (BSE: AUROLAB.BO)
PARMAX.BO vs AUROLAB.BO Comparison August 2026
Parmax Pharma Limited (BSE: PARMAX.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PARMAX.BO stands at 486M. In comparison, AUROLAB.BO has a market cap of 1.5B. Regarding current trading prices, PARMAX.BO is priced at ₹129.90 on the BSE, while AUROLAB.BO trades at ₹235.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PARMAX.BO currently has a P/E ratio of -11.68, whereas AUROLAB.BO's P/E ratio is 39.05. In terms of profitability, PARMAX.BO's ROE is +0.96%, compared to AUROLAB.BO's ROE of +0.08%. Regarding short-term risk, PARMAX.BO is less volatile compared to AUROLAB.BO. This indicates lower risk in terms of short-term price fluctuations for PARMAX.BO.Check AUROLAB.BO's competition here
Parnax Lab Limited (BSE: PARNAXLAB.BO)
PARMAX.BO vs PARNAXLAB.BO Comparison August 2026
Parmax Pharma Limited (BSE: PARMAX.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PARMAX.BO stands at 486M. In comparison, PARNAXLAB.BO has a market cap of 1.4B. Regarding current trading prices, PARMAX.BO is priced at ₹129.90 on the BSE, while PARNAXLAB.BO trades at ₹123.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PARMAX.BO currently has a P/E ratio of -11.68, whereas PARNAXLAB.BO's P/E ratio is 65.26. In terms of profitability, PARMAX.BO's ROE is +0.96%, compared to PARNAXLAB.BO's ROE of +0.10%. Regarding short-term risk, PARMAX.BO is less volatile compared to PARNAXLAB.BO. This indicates lower risk in terms of short-term price fluctuations for PARMAX.BO.Check PARNAXLAB.BO's competition here
Quest Laboratories Ltd. (NSE: QUESTLAB.NS)
PARMAX.BO vs QUESTLAB.NS Comparison August 2026
Parmax Pharma Limited (BSE: PARMAX.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PARMAX.BO stands at 486M. In comparison, QUESTLAB.NS has a market cap of 1.4B. Regarding current trading prices, PARMAX.BO is priced at ₹129.90 on the BSE, while QUESTLAB.NS trades at ₹85.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PARMAX.BO currently has a P/E ratio of -11.68, whereas QUESTLAB.NS's P/E ratio is 10.37. In terms of profitability, PARMAX.BO's ROE is +0.96%, compared to QUESTLAB.NS's ROE of N/A. Regarding short-term risk, PARMAX.BO is less volatile compared to QUESTLAB.NS. This indicates lower risk in terms of short-term price fluctuations for PARMAX.BO.Check QUESTLAB.NS's competition here
Smruthi Organics Limited (BSE: SMRUTHIORG.BO)
PARMAX.BO vs SMRUTHIORG.BO Comparison August 2026
Parmax Pharma Limited (BSE: PARMAX.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PARMAX.BO stands at 486M. In comparison, SMRUTHIORG.BO has a market cap of 1.4B. Regarding current trading prices, PARMAX.BO is priced at ₹129.90 on the BSE, while SMRUTHIORG.BO trades at ₹121.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PARMAX.BO currently has a P/E ratio of -11.68, whereas SMRUTHIORG.BO's P/E ratio is 18.82. In terms of profitability, PARMAX.BO's ROE is +0.96%, compared to SMRUTHIORG.BO's ROE of +0.10%. Regarding short-term risk, PARMAX.BO is less volatile compared to SMRUTHIORG.BO. This indicates lower risk in terms of short-term price fluctuations for PARMAX.BO.Check SMRUTHIORG.BO's competition here
Kimia Biosciences Ltd. (BSE: KIMIABL.BO)
PARMAX.BO vs KIMIABL.BO Comparison August 2026
Parmax Pharma Limited (BSE: PARMAX.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PARMAX.BO stands at 486M. In comparison, KIMIABL.BO has a market cap of 1.3B. Regarding current trading prices, PARMAX.BO is priced at ₹129.90 on the BSE, while KIMIABL.BO trades at ₹27.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PARMAX.BO currently has a P/E ratio of -11.68, whereas KIMIABL.BO's P/E ratio is 31.46. In terms of profitability, PARMAX.BO's ROE is +0.96%, compared to KIMIABL.BO's ROE of +0.55%. Regarding short-term risk, PARMAX.BO is less volatile compared to KIMIABL.BO. This indicates lower risk in terms of short-term price fluctuations for PARMAX.BO.Check KIMIABL.BO's competition here
Lactose (India) Limited (BSE: LACTOSE.BO)
PARMAX.BO vs LACTOSE.BO Comparison August 2026
Parmax Pharma Limited (BSE: PARMAX.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PARMAX.BO stands at 486M. In comparison, LACTOSE.BO has a market cap of 1.3B. Regarding current trading prices, PARMAX.BO is priced at ₹129.90 on the BSE, while LACTOSE.BO trades at ₹100.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PARMAX.BO currently has a P/E ratio of -11.68, whereas LACTOSE.BO's P/E ratio is 20.79. In terms of profitability, PARMAX.BO's ROE is +0.96%, compared to LACTOSE.BO's ROE of +0.11%. Regarding short-term risk, PARMAX.BO is less volatile compared to LACTOSE.BO. This indicates lower risk in terms of short-term price fluctuations for PARMAX.BO.Check LACTOSE.BO's competition here
Pharmaids Pharmaceuticals Limited (BSE: PHARMAID.BO)
PARMAX.BO vs PHARMAID.BO Comparison August 2026
Parmax Pharma Limited (BSE: PARMAX.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PARMAX.BO stands at 486M. In comparison, PHARMAID.BO has a market cap of 1.1B. Regarding current trading prices, PARMAX.BO is priced at ₹129.90 on the BSE, while PHARMAID.BO trades at ₹32.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PARMAX.BO currently has a P/E ratio of -11.68, whereas PHARMAID.BO's P/E ratio is -42.42. In terms of profitability, PARMAX.BO's ROE is +0.96%, compared to PHARMAID.BO's ROE of -0.09%. Regarding short-term risk, PARMAX.BO is less volatile compared to PHARMAID.BO. This indicates lower risk in terms of short-term price fluctuations for PARMAX.BO.Check PHARMAID.BO's competition here
Makers Laboratories Limited (BSE: MAKERSL.BO)
PARMAX.BO vs MAKERSL.BO Comparison August 2026
Parmax Pharma Limited (BSE: PARMAX.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PARMAX.BO stands at 486M. In comparison, MAKERSL.BO has a market cap of 1.1B. Regarding current trading prices, PARMAX.BO is priced at ₹129.90 on the BSE, while MAKERSL.BO trades at ₹185.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PARMAX.BO currently has a P/E ratio of -11.68, whereas MAKERSL.BO's P/E ratio is -146.87. In terms of profitability, PARMAX.BO's ROE is +0.96%, compared to MAKERSL.BO's ROE of +0.04%. Regarding short-term risk, PARMAX.BO is less volatile compared to MAKERSL.BO. This indicates lower risk in terms of short-term price fluctuations for PARMAX.BO.Check MAKERSL.BO's competition here
Tyche Industries Limited (BSE: TYCHE.BO)
PARMAX.BO vs TYCHE.BO Comparison August 2026
Parmax Pharma Limited (BSE: PARMAX.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PARMAX.BO stands at 486M. In comparison, TYCHE.BO has a market cap of 1.1B. Regarding current trading prices, PARMAX.BO is priced at ₹129.90 on the BSE, while TYCHE.BO trades at ₹104.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PARMAX.BO currently has a P/E ratio of -11.68, whereas TYCHE.BO's P/E ratio is 10.55. In terms of profitability, PARMAX.BO's ROE is +0.96%, compared to TYCHE.BO's ROE of +0.03%. Regarding short-term risk, PARMAX.BO is less volatile compared to TYCHE.BO. This indicates lower risk in terms of short-term price fluctuations for PARMAX.BO.Check TYCHE.BO's competition here
Godavari Drugs Limited (BSE: GODAVARI.BO)
PARMAX.BO vs GODAVARI.BO Comparison August 2026
Parmax Pharma Limited (BSE: PARMAX.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PARMAX.BO stands at 486M. In comparison, GODAVARI.BO has a market cap of 1B. Regarding current trading prices, PARMAX.BO is priced at ₹129.90 on the BSE, while GODAVARI.BO trades at ₹101.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PARMAX.BO currently has a P/E ratio of -11.68, whereas GODAVARI.BO's P/E ratio is 23.22. In terms of profitability, PARMAX.BO's ROE is +0.96%, compared to GODAVARI.BO's ROE of +0.08%. Regarding short-term risk, PARMAX.BO is less volatile compared to GODAVARI.BO. This indicates lower risk in terms of short-term price fluctuations for PARMAX.BO.Check GODAVARI.BO's competition here
Sotac Pharmaceuticals Ltd. (NSE: SOTAC.NS)
PARMAX.BO vs SOTAC.NS Comparison August 2026
Parmax Pharma Limited (BSE: PARMAX.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PARMAX.BO stands at 486M. In comparison, SOTAC.NS has a market cap of 995.1M. Regarding current trading prices, PARMAX.BO is priced at ₹129.90 on the BSE, while SOTAC.NS trades at ₹90.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PARMAX.BO currently has a P/E ratio of -11.68, whereas SOTAC.NS's P/E ratio is 11.63. In terms of profitability, PARMAX.BO's ROE is +0.96%, compared to SOTAC.NS's ROE of N/A. Regarding short-term risk, PARMAX.BO is similarly volatile compared to SOTAC.NS. This indicates similar risk in terms of short-term price fluctuations for PARMAX.BO.Check SOTAC.NS's competition here
Denis Chem Lab Limited (BSE: DENISCHEM.BO)
PARMAX.BO vs DENISCHEM.BO Comparison August 2026
Parmax Pharma Limited (BSE: PARMAX.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PARMAX.BO stands at 486M. In comparison, DENISCHEM.BO has a market cap of 991.6M. Regarding current trading prices, PARMAX.BO is priced at ₹129.90 on the BSE, while DENISCHEM.BO trades at ₹71.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PARMAX.BO currently has a P/E ratio of -11.68, whereas DENISCHEM.BO's P/E ratio is 11.79. In terms of profitability, PARMAX.BO's ROE is +0.96%, compared to DENISCHEM.BO's ROE of +0.09%. Regarding short-term risk, PARMAX.BO is less volatile compared to DENISCHEM.BO. This indicates lower risk in terms of short-term price fluctuations for PARMAX.BO.Check DENISCHEM.BO's competition here
Mercury Laboratories Limited (BSE: MERCURYLAB.BO)
PARMAX.BO vs MERCURYLAB.BO Comparison August 2026
Parmax Pharma Limited (BSE: PARMAX.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PARMAX.BO stands at 486M. In comparison, MERCURYLAB.BO has a market cap of 914.9M. Regarding current trading prices, PARMAX.BO is priced at ₹129.90 on the BSE, while MERCURYLAB.BO trades at ₹762.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PARMAX.BO currently has a P/E ratio of -11.68, whereas MERCURYLAB.BO's P/E ratio is 25.04. In terms of profitability, PARMAX.BO's ROE is +0.96%, compared to MERCURYLAB.BO's ROE of +0.07%. Regarding short-term risk, PARMAX.BO is less volatile compared to MERCURYLAB.BO. This indicates lower risk in terms of short-term price fluctuations for PARMAX.BO.Check MERCURYLAB.BO's competition here
Vaishali Pharma Limited (NSE: VAISHALI.NS)
PARMAX.BO vs VAISHALI.NS Comparison August 2026
Parmax Pharma Limited (BSE: PARMAX.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PARMAX.BO stands at 486M. In comparison, VAISHALI.NS has a market cap of 856.5M. Regarding current trading prices, PARMAX.BO is priced at ₹129.90 on the BSE, while VAISHALI.NS trades at ₹7.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PARMAX.BO currently has a P/E ratio of -11.68, whereas VAISHALI.NS's P/E ratio is -2.96. In terms of profitability, PARMAX.BO's ROE is +0.96%, compared to VAISHALI.NS's ROE of +0.06%. Regarding short-term risk, PARMAX.BO is less volatile compared to VAISHALI.NS. This indicates lower risk in terms of short-term price fluctuations for PARMAX.BO.Check VAISHALI.NS's competition here
Concord Drugs Limited (BSE: CONCORD.BO)
PARMAX.BO vs CONCORD.BO Comparison August 2026
Parmax Pharma Limited (BSE: PARMAX.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PARMAX.BO stands at 486M. In comparison, CONCORD.BO has a market cap of 788.6M. Regarding current trading prices, PARMAX.BO is priced at ₹129.90 on the BSE, while CONCORD.BO trades at ₹75.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PARMAX.BO currently has a P/E ratio of -11.68, whereas CONCORD.BO's P/E ratio is 74.75. In terms of profitability, PARMAX.BO's ROE is +0.96%, compared to CONCORD.BO's ROE of +0.03%. Regarding short-term risk, PARMAX.BO is less volatile compared to CONCORD.BO. This indicates lower risk in terms of short-term price fluctuations for PARMAX.BO.Check CONCORD.BO's competition here
Zenith Drugs Ltd. (NSE: ZENITHDRUG.NS)
PARMAX.BO vs ZENITHDRUG.NS Comparison August 2026
Parmax Pharma Limited (BSE: PARMAX.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PARMAX.BO stands at 486M. In comparison, ZENITHDRUG.NS has a market cap of 731.4M. Regarding current trading prices, PARMAX.BO is priced at ₹129.90 on the BSE, while ZENITHDRUG.NS trades at ₹42.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PARMAX.BO currently has a P/E ratio of -11.68, whereas ZENITHDRUG.NS's P/E ratio is 18.54. In terms of profitability, PARMAX.BO's ROE is +0.96%, compared to ZENITHDRUG.NS's ROE of N/A. Regarding short-term risk, PARMAX.BO is less volatile compared to ZENITHDRUG.NS. This indicates lower risk in terms of short-term price fluctuations for PARMAX.BO.Check ZENITHDRUG.NS's competition here
Sunil Healthcare Ltd. (BSE: SUNLOC.BO)
PARMAX.BO vs SUNLOC.BO Comparison August 2026
Parmax Pharma Limited (BSE: PARMAX.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PARMAX.BO stands at 486M. In comparison, SUNLOC.BO has a market cap of 717.8M. Regarding current trading prices, PARMAX.BO is priced at ₹129.90 on the BSE, while SUNLOC.BO trades at ₹70.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PARMAX.BO currently has a P/E ratio of -11.68, whereas SUNLOC.BO's P/E ratio is 17.90. In terms of profitability, PARMAX.BO's ROE is +0.96%, compared to SUNLOC.BO's ROE of +0.05%. Regarding short-term risk, PARMAX.BO is less volatile compared to SUNLOC.BO. This indicates lower risk in terms of short-term price fluctuations for PARMAX.BO.Check SUNLOC.BO's competition here
Source Natural Foods & Herbal Supplements Ltd. (BSE: SOURCENTRL.BO)
PARMAX.BO vs SOURCENTRL.BO Comparison August 2026
Parmax Pharma Limited (BSE: PARMAX.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PARMAX.BO stands at 486M. In comparison, SOURCENTRL.BO has a market cap of 693.6M. Regarding current trading prices, PARMAX.BO is priced at ₹129.90 on the BSE, while SOURCENTRL.BO trades at ₹109.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PARMAX.BO currently has a P/E ratio of -11.68, whereas SOURCENTRL.BO's P/E ratio is 20.41. In terms of profitability, PARMAX.BO's ROE is +0.96%, compared to SOURCENTRL.BO's ROE of +0.14%. Regarding short-term risk, PARMAX.BO is less volatile compared to SOURCENTRL.BO. This indicates lower risk in terms of short-term price fluctuations for PARMAX.BO.Check SOURCENTRL.BO's competition here
Bharat Immunologicals & Biologicals Corporation Limited (BSE: BIBCL.BO)
PARMAX.BO vs BIBCL.BO Comparison August 2026
Parmax Pharma Limited (BSE: PARMAX.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PARMAX.BO stands at 486M. In comparison, BIBCL.BO has a market cap of 682.2M. Regarding current trading prices, PARMAX.BO is priced at ₹129.90 on the BSE, while BIBCL.BO trades at ₹15.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PARMAX.BO currently has a P/E ratio of -11.68, whereas BIBCL.BO's P/E ratio is -4.46. In terms of profitability, PARMAX.BO's ROE is +0.96%, compared to BIBCL.BO's ROE of -0.17%. Regarding short-term risk, PARMAX.BO is less volatile compared to BIBCL.BO. This indicates lower risk in terms of short-term price fluctuations for PARMAX.BO.Check BIBCL.BO's competition here
Vilin Bio Med Ltd. (NSE: VILINBIO.NS)
PARMAX.BO vs VILINBIO.NS Comparison August 2026
Parmax Pharma Limited (BSE: PARMAX.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PARMAX.BO stands at 486M. In comparison, VILINBIO.NS has a market cap of 573.3M. Regarding current trading prices, PARMAX.BO is priced at ₹129.90 on the BSE, while VILINBIO.NS trades at ₹41.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PARMAX.BO currently has a P/E ratio of -11.68, whereas VILINBIO.NS's P/E ratio is 256.88. In terms of profitability, PARMAX.BO's ROE is +0.96%, compared to VILINBIO.NS's ROE of N/A. Regarding short-term risk, PARMAX.BO is similarly volatile compared to VILINBIO.NS. This indicates similar risk in terms of short-term price fluctuations for PARMAX.BO.Check VILINBIO.NS's competition here
Phaarmasia Limited (BSE: PHRMASI.BO)
PARMAX.BO vs PHRMASI.BO Comparison August 2026
Parmax Pharma Limited (BSE: PARMAX.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PARMAX.BO stands at 486M. In comparison, PHRMASI.BO has a market cap of 518.8M. Regarding current trading prices, PARMAX.BO is priced at ₹129.90 on the BSE, while PHRMASI.BO trades at ₹76.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PARMAX.BO currently has a P/E ratio of -11.68, whereas PHRMASI.BO's P/E ratio is -26.42. In terms of profitability, PARMAX.BO's ROE is +0.96%, compared to PHRMASI.BO's ROE of +1.35%. Regarding short-term risk, PARMAX.BO is less volatile compared to PHRMASI.BO. This indicates lower risk in terms of short-term price fluctuations for PARMAX.BO.Check PHRMASI.BO's competition here
Vasundhara Rasayans Limited (BSE: VRL.BO)
PARMAX.BO vs VRL.BO Comparison August 2026
Parmax Pharma Limited (BSE: PARMAX.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PARMAX.BO stands at 486M. In comparison, VRL.BO has a market cap of 489.4M. Regarding current trading prices, PARMAX.BO is priced at ₹129.90 on the BSE, while VRL.BO trades at ₹154.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PARMAX.BO currently has a P/E ratio of -11.68, whereas VRL.BO's P/E ratio is 8.45. In terms of profitability, PARMAX.BO's ROE is +0.96%, compared to VRL.BO's ROE of +0.15%. Regarding short-term risk, PARMAX.BO is less volatile compared to VRL.BO. This indicates lower risk in terms of short-term price fluctuations for PARMAX.BO.Check VRL.BO's competition here
Vista Pharmaceuticals Limited (BSE: VISTAPH.BO)
PARMAX.BO vs VISTAPH.BO Comparison August 2026
Parmax Pharma Limited (BSE: PARMAX.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PARMAX.BO stands at 486M. In comparison, VISTAPH.BO has a market cap of 396.4M. Regarding current trading prices, PARMAX.BO is priced at ₹129.90 on the BSE, while VISTAPH.BO trades at ₹6.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PARMAX.BO currently has a P/E ratio of -11.68, whereas VISTAPH.BO's P/E ratio is -3.34. In terms of profitability, PARMAX.BO's ROE is +0.96%, compared to VISTAPH.BO's ROE of -0.27%. Regarding short-term risk, PARMAX.BO is less volatile compared to VISTAPH.BO. This indicates lower risk in terms of short-term price fluctuations for PARMAX.BO.Check VISTAPH.BO's competition here
Shelter Pharma Limited (BSE: SHELTER.BO)
PARMAX.BO vs SHELTER.BO Comparison August 2026
Parmax Pharma Limited (BSE: PARMAX.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PARMAX.BO stands at 486M. In comparison, SHELTER.BO has a market cap of 370.1M. Regarding current trading prices, PARMAX.BO is priced at ₹129.90 on the BSE, while SHELTER.BO trades at ₹32.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PARMAX.BO currently has a P/E ratio of -11.68, whereas SHELTER.BO's P/E ratio is 6.20. In terms of profitability, PARMAX.BO's ROE is +0.96%, compared to SHELTER.BO's ROE of +0.15%. Regarding short-term risk, PARMAX.BO is less volatile compared to SHELTER.BO. This indicates lower risk in terms of short-term price fluctuations for PARMAX.BO.Check SHELTER.BO's competition here
Sandu Pharmaceuticals Limited (BSE: SANDUPHQ.BO)
PARMAX.BO vs SANDUPHQ.BO Comparison August 2026
Parmax Pharma Limited (BSE: PARMAX.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PARMAX.BO stands at 486M. In comparison, SANDUPHQ.BO has a market cap of 366.2M. Regarding current trading prices, PARMAX.BO is priced at ₹129.90 on the BSE, while SANDUPHQ.BO trades at ₹37.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PARMAX.BO currently has a P/E ratio of -11.68, whereas SANDUPHQ.BO's P/E ratio is 149.45. In terms of profitability, PARMAX.BO's ROE is +0.96%, compared to SANDUPHQ.BO's ROE of +0.04%. Regarding short-term risk, PARMAX.BO is less volatile compared to SANDUPHQ.BO. This indicates lower risk in terms of short-term price fluctuations for PARMAX.BO.Check SANDUPHQ.BO's competition here
Roopa Industries Limited (BSE: ROOPAIND.BO)
PARMAX.BO vs ROOPAIND.BO Comparison August 2026
Parmax Pharma Limited (BSE: PARMAX.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PARMAX.BO stands at 486M. In comparison, ROOPAIND.BO has a market cap of 365.4M. Regarding current trading prices, PARMAX.BO is priced at ₹129.90 on the BSE, while ROOPAIND.BO trades at ₹46.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PARMAX.BO currently has a P/E ratio of -11.68, whereas ROOPAIND.BO's P/E ratio is 357.31. In terms of profitability, PARMAX.BO's ROE is +0.96%, compared to ROOPAIND.BO's ROE of +0.01%. Regarding short-term risk, PARMAX.BO is less volatile compared to ROOPAIND.BO. This indicates lower risk in terms of short-term price fluctuations for PARMAX.BO.Check ROOPAIND.BO's competition here
Deccan Health Care Ltd (BSE: DECCAN.BO)
PARMAX.BO vs DECCAN.BO Comparison August 2026
Parmax Pharma Limited (BSE: PARMAX.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PARMAX.BO stands at 486M. In comparison, DECCAN.BO has a market cap of 333.9M. Regarding current trading prices, PARMAX.BO is priced at ₹129.90 on the BSE, while DECCAN.BO trades at ₹13.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PARMAX.BO currently has a P/E ratio of -11.68, whereas DECCAN.BO's P/E ratio is 13.23. In terms of profitability, PARMAX.BO's ROE is +0.96%, compared to DECCAN.BO's ROE of +0.02%. Regarding short-term risk, PARMAX.BO is less volatile compared to DECCAN.BO. This indicates lower risk in terms of short-term price fluctuations for PARMAX.BO.Check DECCAN.BO's competition here
ANG Lifesciences India Limited (BSE: ANG.BO)
PARMAX.BO vs ANG.BO Comparison August 2026
Parmax Pharma Limited (BSE: PARMAX.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PARMAX.BO stands at 486M. In comparison, ANG.BO has a market cap of 317.8M. Regarding current trading prices, PARMAX.BO is priced at ₹129.90 on the BSE, while ANG.BO trades at ₹24.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PARMAX.BO currently has a P/E ratio of -11.68, whereas ANG.BO's P/E ratio is -2.86. In terms of profitability, PARMAX.BO's ROE is +0.96%, compared to ANG.BO's ROE of -0.22%. Regarding short-term risk, PARMAX.BO is less volatile compared to ANG.BO. This indicates lower risk in terms of short-term price fluctuations for PARMAX.BO.Check ANG.BO's competition here
Panjon Ltd. (BSE: PANJON.BO)
PARMAX.BO vs PANJON.BO Comparison August 2026
Parmax Pharma Limited (BSE: PARMAX.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PARMAX.BO stands at 486M. In comparison, PANJON.BO has a market cap of 306.4M. Regarding current trading prices, PARMAX.BO is priced at ₹129.90 on the BSE, while PANJON.BO trades at ₹17.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PARMAX.BO currently has a P/E ratio of -11.68, whereas PANJON.BO's P/E ratio is 446.25. In terms of profitability, PARMAX.BO's ROE is +0.96%, compared to PANJON.BO's ROE of +0.04%. Regarding short-term risk, PARMAX.BO is less volatile compared to PANJON.BO. This indicates lower risk in terms of short-term price fluctuations for PARMAX.BO.Check PANJON.BO's competition here
Medi-Caps Limited (BSE: MEDICAPQ.BO)
PARMAX.BO vs MEDICAPQ.BO Comparison August 2026
Parmax Pharma Limited (BSE: PARMAX.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PARMAX.BO stands at 486M. In comparison, MEDICAPQ.BO has a market cap of 306.3M. Regarding current trading prices, PARMAX.BO is priced at ₹129.90 on the BSE, while MEDICAPQ.BO trades at ₹24.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PARMAX.BO currently has a P/E ratio of -11.68, whereas MEDICAPQ.BO's P/E ratio is 36.66. In terms of profitability, PARMAX.BO's ROE is +0.96%, compared to MEDICAPQ.BO's ROE of -0.02%. Regarding short-term risk, PARMAX.BO is less volatile compared to MEDICAPQ.BO. This indicates lower risk in terms of short-term price fluctuations for PARMAX.BO.Check MEDICAPQ.BO's competition here
Medicamen Organics Ltd (NSE: MEDIORG.NS)
PARMAX.BO vs MEDIORG.NS Comparison August 2026
Parmax Pharma Limited (BSE: PARMAX.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PARMAX.BO stands at 486M. In comparison, MEDIORG.NS has a market cap of 295.6M. Regarding current trading prices, PARMAX.BO is priced at ₹129.90 on the BSE, while MEDIORG.NS trades at ₹24.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PARMAX.BO currently has a P/E ratio of -11.68, whereas MEDIORG.NS's P/E ratio is -7.13. In terms of profitability, PARMAX.BO's ROE is +0.96%, compared to MEDIORG.NS's ROE of N/A. Regarding short-term risk, PARMAX.BO is similarly volatile compared to MEDIORG.NS. This indicates similar risk in terms of short-term price fluctuations for PARMAX.BO.Check MEDIORG.NS's competition here
Gujarat Terce Laboratories Limited (BSE: GUJTERC.BO)
PARMAX.BO vs GUJTERC.BO Comparison August 2026
Parmax Pharma Limited (BSE: PARMAX.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PARMAX.BO stands at 486M. In comparison, GUJTERC.BO has a market cap of 293.1M. Regarding current trading prices, PARMAX.BO is priced at ₹129.90 on the BSE, while GUJTERC.BO trades at ₹37.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PARMAX.BO currently has a P/E ratio of -11.68, whereas GUJTERC.BO's P/E ratio is 41.48. In terms of profitability, PARMAX.BO's ROE is +0.96%, compared to GUJTERC.BO's ROE of +0.26%. Regarding short-term risk, PARMAX.BO is less volatile compared to GUJTERC.BO. This indicates lower risk in terms of short-term price fluctuations for PARMAX.BO.Check GUJTERC.BO's competition here
Welcure Drugs & Pharmaceuticals Limited (BSE: WELCURE.BO)
PARMAX.BO vs WELCURE.BO Comparison August 2026
Parmax Pharma Limited (BSE: PARMAX.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PARMAX.BO stands at 486M. In comparison, WELCURE.BO has a market cap of 271.9M. Regarding current trading prices, PARMAX.BO is priced at ₹129.90 on the BSE, while WELCURE.BO trades at ₹0.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PARMAX.BO currently has a P/E ratio of -11.68, whereas WELCURE.BO's P/E ratio is -10.93. In terms of profitability, PARMAX.BO's ROE is +0.96%, compared to WELCURE.BO's ROE of -0.34%. Regarding short-term risk, PARMAX.BO is less volatile compared to WELCURE.BO. This indicates lower risk in terms of short-term price fluctuations for PARMAX.BO.Check WELCURE.BO's competition here
Trimurthi Limited (BSE: TRIMURTHI.BO)
PARMAX.BO vs TRIMURTHI.BO Comparison August 2026
Parmax Pharma Limited (BSE: PARMAX.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PARMAX.BO stands at 486M. In comparison, TRIMURTHI.BO has a market cap of 264.8M. Regarding current trading prices, PARMAX.BO is priced at ₹129.90 on the BSE, while TRIMURTHI.BO trades at ₹26.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PARMAX.BO currently has a P/E ratio of -11.68, whereas TRIMURTHI.BO's P/E ratio is 102.35. In terms of profitability, PARMAX.BO's ROE is +0.96%, compared to TRIMURTHI.BO's ROE of +0.02%. Regarding short-term risk, PARMAX.BO is similarly volatile compared to TRIMURTHI.BO. This indicates similar risk in terms of short-term price fluctuations for PARMAX.BO.Check TRIMURTHI.BO's competition here
Ishita Drugs and Industries Limited (BSE: ISHITADR.BO)
PARMAX.BO vs ISHITADR.BO Comparison August 2026
Parmax Pharma Limited (BSE: PARMAX.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PARMAX.BO stands at 486M. In comparison, ISHITADR.BO has a market cap of 228.9M. Regarding current trading prices, PARMAX.BO is priced at ₹129.90 on the BSE, while ISHITADR.BO trades at ₹76.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PARMAX.BO currently has a P/E ratio of -11.68, whereas ISHITADR.BO's P/E ratio is 192.02. In terms of profitability, PARMAX.BO's ROE is +0.96%, compared to ISHITADR.BO's ROE of +0.06%. Regarding short-term risk, PARMAX.BO is less volatile compared to ISHITADR.BO. This indicates lower risk in terms of short-term price fluctuations for PARMAX.BO.Check ISHITADR.BO's competition here
Chemo Pharma Laboratories Limited (BSE: CHEMOPH.BO)
PARMAX.BO vs CHEMOPH.BO Comparison August 2026
Parmax Pharma Limited (BSE: PARMAX.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PARMAX.BO stands at 486M. In comparison, CHEMOPH.BO has a market cap of 196.3M. Regarding current trading prices, PARMAX.BO is priced at ₹129.90 on the BSE, while CHEMOPH.BO trades at ₹130.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PARMAX.BO currently has a P/E ratio of -11.68, whereas CHEMOPH.BO's P/E ratio is -1.61. In terms of profitability, PARMAX.BO's ROE is +0.96%, compared to CHEMOPH.BO's ROE of -0.92%. Regarding short-term risk, PARMAX.BO is less volatile compared to CHEMOPH.BO. This indicates lower risk in terms of short-term price fluctuations for PARMAX.BO.Check CHEMOPH.BO's competition here
Colinz Laboratories Limited (BSE: COLINZ.BO)
PARMAX.BO vs COLINZ.BO Comparison August 2026
Parmax Pharma Limited (BSE: PARMAX.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PARMAX.BO stands at 486M. In comparison, COLINZ.BO has a market cap of 195.7M. Regarding current trading prices, PARMAX.BO is priced at ₹129.90 on the BSE, while COLINZ.BO trades at ₹74.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PARMAX.BO currently has a P/E ratio of -11.68, whereas COLINZ.BO's P/E ratio is 184.93. In terms of profitability, PARMAX.BO's ROE is +0.96%, compared to COLINZ.BO's ROE of +0.28%. Regarding short-term risk, PARMAX.BO is less volatile compared to COLINZ.BO. This indicates lower risk in terms of short-term price fluctuations for PARMAX.BO.Check COLINZ.BO's competition here
Bacil Pharma Limited (BSE: BACPHAR.BO)
PARMAX.BO vs BACPHAR.BO Comparison August 2026
Parmax Pharma Limited (BSE: PARMAX.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PARMAX.BO stands at 486M. In comparison, BACPHAR.BO has a market cap of 176.5M. Regarding current trading prices, PARMAX.BO is priced at ₹129.90 on the BSE, while BACPHAR.BO trades at ₹12.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PARMAX.BO currently has a P/E ratio of -11.68, whereas BACPHAR.BO's P/E ratio is 41.20. In terms of profitability, PARMAX.BO's ROE is +0.96%, compared to BACPHAR.BO's ROE of +0.03%. Regarding short-term risk, PARMAX.BO is less volatile compared to BACPHAR.BO. This indicates lower risk in terms of short-term price fluctuations for PARMAX.BO.Check BACPHAR.BO's competition here
Sunrest Lifescience Ltd. (NSE: SUNREST.NS)
PARMAX.BO vs SUNREST.NS Comparison August 2026
Parmax Pharma Limited (BSE: PARMAX.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PARMAX.BO stands at 486M. In comparison, SUNREST.NS has a market cap of 175.9M. Regarding current trading prices, PARMAX.BO is priced at ₹129.90 on the BSE, while SUNREST.NS trades at ₹41.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PARMAX.BO currently has a P/E ratio of -11.68, whereas SUNREST.NS's P/E ratio is 8.78. In terms of profitability, PARMAX.BO's ROE is +0.96%, compared to SUNREST.NS's ROE of N/A. Regarding short-term risk, PARMAX.BO is less volatile compared to SUNREST.NS. This indicates lower risk in terms of short-term price fluctuations for PARMAX.BO.Check SUNREST.NS's competition here
Zenlabs Ethica Limited (BSE: ZENLABS.BO)
PARMAX.BO vs ZENLABS.BO Comparison August 2026
Parmax Pharma Limited (BSE: PARMAX.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PARMAX.BO stands at 486M. In comparison, ZENLABS.BO has a market cap of 169.3M. Regarding current trading prices, PARMAX.BO is priced at ₹129.90 on the BSE, while ZENLABS.BO trades at ₹26.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PARMAX.BO currently has a P/E ratio of -11.68, whereas ZENLABS.BO's P/E ratio is -8.75. In terms of profitability, PARMAX.BO's ROE is +0.96%, compared to ZENLABS.BO's ROE of -0.19%. Regarding short-term risk, PARMAX.BO is less volatile compared to ZENLABS.BO. This indicates lower risk in terms of short-term price fluctuations for PARMAX.BO.Check ZENLABS.BO's competition here
Norris Medicines Limited (BSE: NORRIS.BO)
PARMAX.BO vs NORRIS.BO Comparison August 2026
Parmax Pharma Limited (BSE: PARMAX.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PARMAX.BO stands at 486M. In comparison, NORRIS.BO has a market cap of 156M. Regarding current trading prices, PARMAX.BO is priced at ₹129.90 on the BSE, while NORRIS.BO trades at ₹15.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PARMAX.BO currently has a P/E ratio of -11.68, whereas NORRIS.BO's P/E ratio is N/A. In terms of profitability, PARMAX.BO's ROE is +0.96%, compared to NORRIS.BO's ROE of +0.02%. Regarding short-term risk, PARMAX.BO is less volatile compared to NORRIS.BO. This indicates lower risk in terms of short-term price fluctuations for PARMAX.BO.Check NORRIS.BO's competition here
Shamrock Industrial Co. Ltd. (BSE: SHAMROIN.BO)
PARMAX.BO vs SHAMROIN.BO Comparison August 2026
Parmax Pharma Limited (BSE: PARMAX.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PARMAX.BO stands at 486M. In comparison, SHAMROIN.BO has a market cap of 140.9M. Regarding current trading prices, PARMAX.BO is priced at ₹129.90 on the BSE, while SHAMROIN.BO trades at ₹25.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PARMAX.BO currently has a P/E ratio of -11.68, whereas SHAMROIN.BO's P/E ratio is -282.42. In terms of profitability, PARMAX.BO's ROE is +0.96%, compared to SHAMROIN.BO's ROE of -0.98%. Regarding short-term risk, PARMAX.BO is similarly volatile compared to SHAMROIN.BO. This indicates similar risk in terms of short-term price fluctuations for PARMAX.BO.Check SHAMROIN.BO's competition here
Emmessar Biotech & Nutrition Limited (BSE: EMMESSA.BO)
PARMAX.BO vs EMMESSA.BO Comparison August 2026
Parmax Pharma Limited (BSE: PARMAX.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PARMAX.BO stands at 486M. In comparison, EMMESSA.BO has a market cap of 119.5M. Regarding current trading prices, PARMAX.BO is priced at ₹129.90 on the BSE, while EMMESSA.BO trades at ₹23.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PARMAX.BO currently has a P/E ratio of -11.68, whereas EMMESSA.BO's P/E ratio is 79.73. In terms of profitability, PARMAX.BO's ROE is +0.96%, compared to EMMESSA.BO's ROE of +0.05%. Regarding short-term risk, PARMAX.BO is less volatile compared to EMMESSA.BO. This indicates lower risk in terms of short-term price fluctuations for PARMAX.BO.Check EMMESSA.BO's competition here
Kobo Biotech Ltd. (BSE: KOBO.BO)
PARMAX.BO vs KOBO.BO Comparison August 2026
Parmax Pharma Limited (BSE: PARMAX.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PARMAX.BO stands at 486M. In comparison, KOBO.BO has a market cap of 115.8M. Regarding current trading prices, PARMAX.BO is priced at ₹129.90 on the BSE, while KOBO.BO trades at ₹4.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PARMAX.BO currently has a P/E ratio of -11.68, whereas KOBO.BO's P/E ratio is -9.40. In terms of profitability, PARMAX.BO's ROE is +0.96%, compared to KOBO.BO's ROE of +0.04%. Regarding short-term risk, PARMAX.BO is similarly volatile compared to KOBO.BO. This indicates similar risk in terms of short-term price fluctuations for PARMAX.BO.Check KOBO.BO's competition here
Beryl Drugs Limited (BSE: BERLDRG.BO)
PARMAX.BO vs BERLDRG.BO Comparison August 2026
Parmax Pharma Limited (BSE: PARMAX.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PARMAX.BO stands at 486M. In comparison, BERLDRG.BO has a market cap of 115.6M. Regarding current trading prices, PARMAX.BO is priced at ₹129.90 on the BSE, while BERLDRG.BO trades at ₹22.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PARMAX.BO currently has a P/E ratio of -11.68, whereas BERLDRG.BO's P/E ratio is 37.13. In terms of profitability, PARMAX.BO's ROE is +0.96%, compared to BERLDRG.BO's ROE of +0.07%. Regarding short-term risk, PARMAX.BO is less volatile compared to BERLDRG.BO. This indicates lower risk in terms of short-term price fluctuations for PARMAX.BO.Check BERLDRG.BO's competition here
Trinity League India Limited (BSE: TRINITYLEA.BO)
PARMAX.BO vs TRINITYLEA.BO Comparison August 2026
Parmax Pharma Limited (BSE: PARMAX.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PARMAX.BO stands at 486M. In comparison, TRINITYLEA.BO has a market cap of 76M. Regarding current trading prices, PARMAX.BO is priced at ₹129.90 on the BSE, while TRINITYLEA.BO trades at ₹9.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PARMAX.BO currently has a P/E ratio of -11.68, whereas TRINITYLEA.BO's P/E ratio is -48.00. In terms of profitability, PARMAX.BO's ROE is +0.96%, compared to TRINITYLEA.BO's ROE of -0.06%. Regarding short-term risk, PARMAX.BO is less volatile compared to TRINITYLEA.BO. This indicates lower risk in terms of short-term price fluctuations for PARMAX.BO.Check TRINITYLEA.BO's competition here
Ganga Pharmaceuticals Limited (BSE: GANGAPHARM.BO)
PARMAX.BO vs GANGAPHARM.BO Comparison August 2026
Parmax Pharma Limited (BSE: PARMAX.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PARMAX.BO stands at 486M. In comparison, GANGAPHARM.BO has a market cap of 70.9M. Regarding current trading prices, PARMAX.BO is priced at ₹129.90 on the BSE, while GANGAPHARM.BO trades at ₹12.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PARMAX.BO currently has a P/E ratio of -11.68, whereas GANGAPHARM.BO's P/E ratio is 109.09. In terms of profitability, PARMAX.BO's ROE is +0.96%, compared to GANGAPHARM.BO's ROE of +0.01%. Regarding short-term risk, PARMAX.BO is similarly volatile compared to GANGAPHARM.BO. This indicates similar risk in terms of short-term price fluctuations for PARMAX.BO.Check GANGAPHARM.BO's competition here
Vivanza Biosciences Limited (BSE: VIVANZA.BO)
PARMAX.BO vs VIVANZA.BO Comparison August 2026
Parmax Pharma Limited (BSE: PARMAX.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PARMAX.BO stands at 486M. In comparison, VIVANZA.BO has a market cap of 70M. Regarding current trading prices, PARMAX.BO is priced at ₹129.90 on the BSE, while VIVANZA.BO trades at ₹1.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PARMAX.BO currently has a P/E ratio of -11.68, whereas VIVANZA.BO's P/E ratio is -180.41. In terms of profitability, PARMAX.BO's ROE is +0.96%, compared to VIVANZA.BO's ROE of +0.10%. Regarding short-term risk, PARMAX.BO is less volatile compared to VIVANZA.BO. This indicates lower risk in terms of short-term price fluctuations for PARMAX.BO.Check VIVANZA.BO's competition here
Hindustan Bio Sciences Limited (BSE: HINDBIO.BO)
PARMAX.BO vs HINDBIO.BO Comparison August 2026
Parmax Pharma Limited (BSE: PARMAX.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PARMAX.BO stands at 486M. In comparison, HINDBIO.BO has a market cap of 68.8M. Regarding current trading prices, PARMAX.BO is priced at ₹129.90 on the BSE, while HINDBIO.BO trades at ₹6.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PARMAX.BO currently has a P/E ratio of -11.68, whereas HINDBIO.BO's P/E ratio is 45.52. In terms of profitability, PARMAX.BO's ROE is +0.96%, compared to HINDBIO.BO's ROE of -0.24%. Regarding short-term risk, PARMAX.BO is less volatile compared to HINDBIO.BO. This indicates lower risk in terms of short-term price fluctuations for PARMAX.BO.Check HINDBIO.BO's competition here
Adline Chem Lab Ltd. (BSE: ADLINE.BO)
PARMAX.BO vs ADLINE.BO Comparison August 2026
Parmax Pharma Limited (BSE: PARMAX.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PARMAX.BO stands at 486M. In comparison, ADLINE.BO has a market cap of 65.4M. Regarding current trading prices, PARMAX.BO is priced at ₹129.90 on the BSE, while ADLINE.BO trades at ₹11.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PARMAX.BO currently has a P/E ratio of -11.68, whereas ADLINE.BO's P/E ratio is N/A. In terms of profitability, PARMAX.BO's ROE is +0.96%, compared to ADLINE.BO's ROE of N/A. Regarding short-term risk, PARMAX.BO is similarly volatile compared to ADLINE.BO. This indicates similar risk in terms of short-term price fluctuations for PARMAX.BO.Check ADLINE.BO's competition here
Tiaan Consumer Ltd. (BSE: TIAANC.BO)
PARMAX.BO vs TIAANC.BO Comparison August 2026
Parmax Pharma Limited (BSE: PARMAX.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PARMAX.BO stands at 486M. In comparison, TIAANC.BO has a market cap of 64.5M. Regarding current trading prices, PARMAX.BO is priced at ₹129.90 on the BSE, while TIAANC.BO trades at ₹6.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PARMAX.BO currently has a P/E ratio of -11.68, whereas TIAANC.BO's P/E ratio is -48.31. In terms of profitability, PARMAX.BO's ROE is +0.96%, compared to TIAANC.BO's ROE of -0.01%. Regarding short-term risk, PARMAX.BO is less volatile compared to TIAANC.BO. This indicates lower risk in terms of short-term price fluctuations for PARMAX.BO.Check TIAANC.BO's competition here
Decipher Labs Ltd. (BSE: DECIPHER.BO)
PARMAX.BO vs DECIPHER.BO Comparison August 2026
Parmax Pharma Limited (BSE: PARMAX.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PARMAX.BO stands at 486M. In comparison, DECIPHER.BO has a market cap of 58.1M. Regarding current trading prices, PARMAX.BO is priced at ₹129.90 on the BSE, while DECIPHER.BO trades at ₹5.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PARMAX.BO currently has a P/E ratio of -11.68, whereas DECIPHER.BO's P/E ratio is -0.72. In terms of profitability, PARMAX.BO's ROE is +0.96%, compared to DECIPHER.BO's ROE of -0.09%. Regarding short-term risk, PARMAX.BO is less volatile compared to DECIPHER.BO. This indicates lower risk in terms of short-term price fluctuations for PARMAX.BO.Check DECIPHER.BO's competition here
Fabino Enterprises Ltd (BSE: FABINO.BO)
PARMAX.BO vs FABINO.BO Comparison August 2026
Parmax Pharma Limited (BSE: PARMAX.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PARMAX.BO stands at 486M. In comparison, FABINO.BO has a market cap of 42.7M. Regarding current trading prices, PARMAX.BO is priced at ₹129.90 on the BSE, while FABINO.BO trades at ₹20.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PARMAX.BO currently has a P/E ratio of -11.68, whereas FABINO.BO's P/E ratio is -7.64. In terms of profitability, PARMAX.BO's ROE is +0.96%, compared to FABINO.BO's ROE of +0.01%. Regarding short-term risk, PARMAX.BO is similarly volatile compared to FABINO.BO. This indicates similar risk in terms of short-term price fluctuations for PARMAX.BO.Check FABINO.BO's competition here
TMT (India) Ltd. (BSE: TMTIND-B1.BO)
PARMAX.BO vs TMTIND-B1.BO Comparison August 2026
Parmax Pharma Limited (BSE: PARMAX.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PARMAX.BO stands at 486M. In comparison, TMTIND-B1.BO has a market cap of 41.9M. Regarding current trading prices, PARMAX.BO is priced at ₹129.90 on the BSE, while TMTIND-B1.BO trades at ₹8.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PARMAX.BO currently has a P/E ratio of -11.68, whereas TMTIND-B1.BO's P/E ratio is -46.94. In terms of profitability, PARMAX.BO's ROE is +0.96%, compared to TMTIND-B1.BO's ROE of N/A. Regarding short-term risk, PARMAX.BO is similarly volatile compared to TMTIND-B1.BO. This indicates similar risk in terms of short-term price fluctuations for PARMAX.BO.Check TMTIND-B1.BO's competition here
Patidar Buildcon Limited (BSE: PATIDAR.BO)
PARMAX.BO vs PATIDAR.BO Comparison August 2026
Parmax Pharma Limited (BSE: PARMAX.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PARMAX.BO stands at 486M. In comparison, PATIDAR.BO has a market cap of 27.5M. Regarding current trading prices, PARMAX.BO is priced at ₹129.90 on the BSE, while PATIDAR.BO trades at ₹5.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PARMAX.BO currently has a P/E ratio of -11.68, whereas PATIDAR.BO's P/E ratio is -11.63. In terms of profitability, PARMAX.BO's ROE is +0.96%, compared to PATIDAR.BO's ROE of -0.04%. Regarding short-term risk, PARMAX.BO is similarly volatile compared to PATIDAR.BO. This indicates similar risk in terms of short-term price fluctuations for PARMAX.BO.Check PATIDAR.BO's competition here